Key facts
- It has raised $43.5M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Baidu Ventures, YuanBio Venture Capital, Co-Win Ventures, New Alliance Capital, Takeda Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Degron Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Degron Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Degron Therapeutics
Developer of molecular glue-based small-molecule drugs intended for therapeutic development for complex diseases. The company offers innovative protein degradation drugs; it uses molecular glial protein degradation platform technology to discover new drugs, enabling clients to improve treatment efficiency.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 35
- Website
- degrontx.com/
- Ownership
- Privately Held (backing)
Degron Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Degron Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Degron Therapeutics in its N-PORT filings yet. We sweep new filings monthly.